Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

Abstract Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecul...

Full description

Bibliographic Details
Main Authors: Carolina Pavlovsky, Bianca Vasconcelos Cordoba, María Belén Sanchez, Beatriz Moiraghi, Ana Varela, Rosario Custidiano, Isolda Fernandez, Maria Josefina Freitas, Maria Verónica Ventriglia, Georgina Bendek, Romina Mariano, María José Mela Osorio, Miguel Angel Pavlovsky, Ana García de Labanca, Cecilia Foncuberta, Isabel Giere, Masiel Vera, Mariana Juni, Jose Mordoh, Julio Cesar Sanchez Avalos, Gerardo Cueto, Silvia Miranda, Estrella Mariel Levy, Michele Bianchini
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Journal of Hematology & Oncology
Subjects:
Chronic myeloid leukemia
Treatment free remission
Cytokines
Predictive factors
Online Access:https://doi.org/10.1186/s13045-023-01440-6

Internet

https://doi.org/10.1186/s13045-023-01440-6

Similar Items